Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temodal in Progressive Breast Cancer
NCT00005054Phase 2Unknown
- Sponsor
- The Christie
- Start
- May 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in breast cancer, sponsored by The Christie. Primary endpoints: Tumor Response, Progression-Free Survival and 1 more. Status: unknown.
02
Drugs
temozolomide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00005054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005054.